GTI-2501

GTI-2501 Uses, Dosage, Side Effects, Food Interaction and all others data.

GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. Initial testing has demonstrated strong antitumor activity in preclinical studies in prostate cancer and a variety of other tumor types.

Trade Name GTI-2501
Generic GTI-2501
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
GTI-2501
GTI-2501

Uses

Investigated for use/treatment in prostate cancer and solid tumors.

How GTI-2501 works

GTI-2501 is an antisense oligonucleotide complementary to the R1 component of ribonucleotide reductase, which component is essential for DNA replication and tumor cell proliferation. GTI-2501 is designed to exert its activity by specific downregulation of the R1 component of ribonucleotide reductase. In preclinical studies, GTI-2501 showed significant antitumor activity against prostate cancer and a variety of other tumor types including colon, pancreas, NSCLC, breast, ovary, melanoma, brain (glioblastoma-astrocytoma), renal, cervical, lymphoma and leukemia.

Innovators Monograph

You find simplified version here GTI-2501

*** Taking medicines without doctor's advice can cause long-term problems.
Share